// App-Quantinova.ai

BSH2020‐PO‐043 : Immunological effects of ponatinib therapy in patients with chronic myeloid leukaemia

Researchers

Presenter

  • P. Harrington

Principal Investigators

  • D. Radia

  • M. Lim

  • R. Dillon

  • S. Kordasti

  • K. Rezvani

  • C. Harrison

  • H. de Lavallade

Medical Centers

  • Department of Haematology, Guy's and St Thomas’ NHS Foundation Trust

  • School of Cancer and Pharmaceutical Science, King's College London, London, UK UK

  • Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

  • Haematological Medicine, Kings College Hospital, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Natural Killer cells

  • Interferon-gamma

  • Signal transducer and activator of transcription 5

  • Regulatory T cells

  • T-cell receptor

Drug/Treatment

  • Ponatinib

  • ZAP70

  • Interferon Gamma

  • OKT3

  • IL-4

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved